Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates
27.5.2026 17:00:00 EEST | Business Wire | Press release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features.
The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing.
The Market Shift: Financing as a Growth Lever for B2B Tech Companies
The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting.
Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and decisioned in under 30 seconds.
“For a cybersecurity company like Barracuda, the ability to offer customers flexible subscription financing, with and through our partner ecosystem — without the delays of traditional lenders — directly translates to faster deal cycles and stronger customer relationships. Capchase has become a genuine competitive advantage for our channel.”
— Geoff Waters, CRO, Barracuda Networks
In today’s macroeconomic environment, buyers face budget constraints and tighter cash controls from their CFOs, who prioritize cash preservation over sales enablement. Capchase helps sales leaders access the tech they need without requiring large, upfront payments or waiting for the customer’s next budget approval cycle.
“What we look for in a financing partner is straightforward: they need to move at the speed of the channel. Capchase does exactly that. Quotes turn into approvals in minutes—not days—and that velocity carries through to our sellers and our clients. That’s the standard partners should be held to in 2026.”
— Rob Zack, Vice Chair, MicroAge
The Only Salesforce-Native Financing Platform for Enterprise Tech Vendors
Capchase is the only platform that’s both the lender and the lending infrastructure. Banks have capital but lack speed and software. SaaS and POS partners don’t lend capital directly. Capchase offers both at the speed of tech.
"We moved away from our previous financing provider when it became clear they couldn’t match the speed, technology, or certainty of funding that Capchase offers. What once required hours of forms, email chains, and back-and-forth with customers now happens in minutes directly within Salesforce. Financing used to be a friction point in our sales motion. With Capchase, it became a growth driver."
— Stephanie Southard, Head of Sales, Datarails
AI-Enabled Underwriting & Lending: From Days to Minutes
Capchase AI powers core platform functionality such as underwriting, proposals, purchase order generation, and deal management workflows. But today, Capchase launches a new AI-native product to further streamline the financing process.
Our Agentic Lending Coordinator collects quotes, POs, emails, and other documents, and converts them into an executable loan package instantly. It then manages multi-party collaboration between vendors, partners, and buyers from package review through signing. Since the beta launch, Capchase customers have seen an 8-hour process condensed into a 60-second automation.
Fortune 500 Tech Companies Run on Capchase’s Financing Infrastructure
Capchase’s category leadership is reflected in its growing customer ecosystem, including Barracuda (mission-critical cybersecurity platforms), CDW and Insight (the largest IT solution providers in North America), and MicroAge (which extends financing to the mid-market segment via the reseller channel).
These partnerships highlight where financing demand is strongest: multi-party enterprise tech deals where speed determines outcomes.
“Traditional financing lenders have capital but lack technology, speed, and scale. By becoming both the lender and the infrastructure for vendor financing, we’re making it a growth lever for sales teams, rather than a bottleneck.”
— Miguel Fernandez, CEO & Co-Founder, Capchase
About Capchase
Capchase is a vendor financing platform and lender that helps enterprise technology companies close more deals by offering instant financing to their buyers. We’ve transformed the vendor financing process by embedding underwriting, origination, and deal management directly into sales workflows, and generating loan proposals and documents with the help of AI agents.
Founded in 2020, Capchase serves enterprise tech companies and channel partners, including Barracuda, Verkada, Motive, Okta, Datarails, CDW, Netradyne, and Insight. Capchase is based in New York, with offices in San Francisco and Madrid, and is backed by leading fintech investors QED, Invesco, Thomvest, and 01 Advisors.
Vendor financing at the speed of tech.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527647157/en/
Contacts
Media contact: Ally Basak, Kindling Collective
415-990-8370
ally@kindling-collective.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom